ThermoGenesis (KOOL) surges 32% after the company reported, along with its partner TotipotentRX, statistically significant results in five key areas in a Phase Ib trial of the latter's CLIRST stem-cell therapy for treating critical limb ischemia.
The study comprised 17 patients and achieved its primary safety and secondary efficacy endpoints at 12 months.
The areas that were assessed included survival rates that didn't require major amputations, a fall in resting and walking pain, improved walking distance and open wound healing.
Critical limb ischemia is a severe blockage in the arteries in the lower extremities. (PR)